申请人:Pfizer Inc.
公开号:US06670362B2
公开(公告)日:2003-12-30
Compounds of formula (I), pharmaceutical formulations thereof and the use of such compounds for treating endothelin mediated diseases or conditions are described herein.
The compounds of the present invention have affinity for endothelin receptors, are selective for ETA over ETB, and thus are useful in the treatment of conditions mediated by endothelin.
本文描述了化学式(I)的化合物、制药配方以及使用这些化合物治疗内皮素介导的疾病或症状。本发明的化合物具有内皮素受体亲和力,对ETA选择性较高,因此可用于治疗内皮素介导的疾病或症状。